Dymon Asia Capital Singapore PTE. LTD. Reduces Stock Holdings in Pfizer Inc. (NYSE:PFE)

Dymon Asia Capital Singapore PTE. LTD. lowered its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 36.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 31,600 shares of the biopharmaceutical company's stock after selling 18,400 shares during the quarter. Dymon Asia Capital Singapore PTE. LTD.'s holdings in Pfizer were worth $838,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. TD Private Client Wealth LLC grew its holdings in shares of Pfizer by 2.7% during the 3rd quarter. TD Private Client Wealth LLC now owns 124,712 shares of the biopharmaceutical company's stock worth $3,609,000 after purchasing an additional 3,307 shares during the period. Passumpsic Savings Bank lifted its position in shares of Pfizer by 8.4% during the 3rd quarter. Passumpsic Savings Bank now owns 25,680 shares of the biopharmaceutical company's stock worth $743,000 after buying an additional 1,998 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Pfizer in the 3rd quarter valued at about $1,499,000. Westside Investment Management Inc. boosted its stake in Pfizer by 7.7% during the 3rd quarter. Westside Investment Management Inc. now owns 14,008 shares of the biopharmaceutical company's stock worth $404,000 after purchasing an additional 1,004 shares during the period. Finally, Diamant Asset Management Inc. raised its stake in Pfizer by 8.4% during the 3rd quarter. Diamant Asset Management Inc. now owns 8,515 shares of the biopharmaceutical company's stock valued at $246,000 after acquiring an additional 660 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Remove Ads

Analyst Ratings Changes

Several research analysts have issued reports on PFE shares. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. UBS Group lowered their target price on shares of Pfizer from $28.00 to $24.00 and set a "neutral" rating for the company in a research note on Tuesday, April 8th. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Truist Financial decreased their target price on Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a report on Wednesday, December 18th. Finally, Citigroup reiterated a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $31.07.

Pfizer Price Performance

Shares of Pfizer stock traded up $0.19 during midday trading on Monday, reaching $22.10. The company had a trading volume of 61,136,100 shares, compared to its average volume of 48,303,832. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The company has a market capitalization of $125.34 billion, a price-to-earnings ratio of 15.67, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. The stock has a fifty day simple moving average of $25.25 and a 200 day simple moving average of $26.38.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm's revenue was up 24.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.10 EPS. As a group, equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Insider Activity at Pfizer

In related news, Director Ronald E. Blaylock bought 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. 0.06% of the stock is owned by company insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.